Progenics Pharma (PGNX) Misses Q3 EPS by 3c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of $0.52, $0.03 worse than the analyst estimate of $0.55. Revenue for the quarter came in at $53.9 million versus the consensus estimate of $52.9 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c